124 related articles for article (PubMed ID: 1824825)
1. A role for the interleukin 1 receptor in the synergistic antitumor effects of human interleukin 1 alpha and etoposide against human melanoma cells.
Usui N; Mimnaugh EG; Sinha BK
Cancer Res; 1991 Feb; 51(3):769-74. PubMed ID: 1824825
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antitumor activity of etoposide and human interleukin-1 alpha against human melanoma cells.
Usui N; Mimnaugh EG; Sinha BK
J Natl Cancer Inst; 1989 Dec; 81(24):1904-9. PubMed ID: 2593167
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antiproliferative effects of the combination of interleukin-1 alpha and doxorubicin against human melanoma cells.
Mimnaugh EG; Monti E; Sebers S; Stetler-Stevenson M; Sinha BK
Oncol Res; 1992; 4(10):401-12. PubMed ID: 1292755
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of human recombinant interleukin-1 alpha and etoposide against human tumor cells: mechanism for synergism in vitro and activity in vivo.
Usui N; Matsushima K; Pilaro AM; Longo DL; Wiltrout RH
Biotherapy; 1996; 9(4):199-208. PubMed ID: 9012539
[TBL] [Abstract][Full Text] [Related]
5. Enhanced cytotoxicity with interleukin-1 alpha and 5-fluorouracil in HCT116 colon cancer cells.
Geoffroy FJ; Allegra CJ; Sinha B; Grem JL
Oncol Res; 1994; 6(12):581-91. PubMed ID: 7787251
[TBL] [Abstract][Full Text] [Related]
6. Contribution of IL-6 to the antiproliferative effect of IL-1 and tumor necrosis factor on tumor cell lines.
Morinaga Y; Suzuki H; Takatsuki F; Akiyama Y; Taniyama T; Matsushima K; Onozaki K
J Immunol; 1989 Dec; 143(11):3538-42. PubMed ID: 2584706
[TBL] [Abstract][Full Text] [Related]
7. IL-1 and IL-4 modulate IL-1 receptor expression in a murine T cell line.
Lacey DL; Erdmann JM
J Immunol; 1990 Dec; 145(12):4145-53. PubMed ID: 2147936
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 1 alpha and interleukin 1 beta bind to the same receptor on T cells.
Kilian PL; Kaffka KL; Stern AS; Woehle D; Benjamin WR; Dechiara TM; Gubler U; Farrar JJ; Mizel SB; Lomedico PT
J Immunol; 1986 Jun; 136(12):4509-14. PubMed ID: 2940296
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antitumor activity of cisplatin and interleukin 1 in sensitive and resistant solid tumors.
Braunschweiger PG; Basrur VS; Santos O; Markoe AM; Houdek PV; Schwade JG
Cancer Res; 1993 Mar; 53(5):1091-7. PubMed ID: 8439953
[TBL] [Abstract][Full Text] [Related]
10. Identification of a high-affinity receptor for interleukin 1 alpha and interleukin 1 beta on cultured human rheumatoid synovial cells.
Chin J; Rupp E; Cameron PM; MacNaul KL; Lotke PA; Tocci MJ; Schmidt JA; Bayne EK
J Clin Invest; 1988 Aug; 82(2):420-6. PubMed ID: 2969918
[TBL] [Abstract][Full Text] [Related]
11. Synergistic interactions of etoposide and interleukin-1 alpha are not due to DNA damage in human melanoma cells.
Monti E; Mimnaugh EG; Sinha BK
Biochim Biophys Acta; 1993 Jan; 1180(3):231-5. PubMed ID: 8422427
[TBL] [Abstract][Full Text] [Related]
12. IL-1 binds to high affinity receptors on human osteosarcoma cells and potentiates prostaglandin E2 stimulation of cAMP production.
Rodan SB; Wesolowski G; Chin J; Limjuco GA; Schmidt JA; Rodan GA
J Immunol; 1990 Aug; 145(4):1231-7. PubMed ID: 2166111
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-alpha and interleukin 1.
Jelinek DF; Lipsky PE
J Immunol; 1987 Nov; 139(9):2970-6. PubMed ID: 3117883
[TBL] [Abstract][Full Text] [Related]
14. Synergistic and antagonistic effects of IL-1 alpha and IL-4, respectively, on the IL-2-dependent growth of a T cell receptor-gamma delta+ human T leukemia cell line.
Santoli D; O'Connor R; Cesano A; Phillips P; Colt TL; Lange B; Clark SC; Rovera G
J Immunol; 1990 Jun; 144(12):4703-11. PubMed ID: 2351825
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effects of IL-7 and IL-12 on human T cell activation.
Mehrotra PT; Grant AJ; Siegel JP
J Immunol; 1995 May; 154(10):5093-102. PubMed ID: 7730615
[TBL] [Abstract][Full Text] [Related]
16. Selection and characterization of a variant of human melanoma cell line, A375 resistant to growth inhibitory effects of oncostatin M (OM): coresistant to interleukin 6 (IL-6).
McDonald VL; Dick KO; Malik N; Shoyab M
Growth Factors; 1993; 9(3):167-75. PubMed ID: 8274294
[TBL] [Abstract][Full Text] [Related]
17. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor and IL-1 associated with plasma membranes of activated human monocytes lyse monokine-sensitive but not monokine-resistant tumor cells whereas viable activated monocytes lyse both.
Ichinose Y; Bakouche O; Tsao JY; Fidler IJ
J Immunol; 1988 Jul; 141(2):512-8. PubMed ID: 3260254
[TBL] [Abstract][Full Text] [Related]
19. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
20. The combination of different types of antitumor topoisomerase II inhibitors, ICRF-193 and VP-16, has synergistic and antagonistic effects on cell survival, depending on treatment schedule.
Ishida R; Iwai M; Hara A; Andoh T
Anticancer Res; 1996; 16(5A):2735-40. PubMed ID: 8917380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
